The Effects of Written Emotional Disclosure on Eating Disorder Pathology in a Clinical Eating Disordered Population

The recruitment status of this study is unknown because the information has not been verified recently.
Verified September 2008 by Penn State University.
Recruitment status was  Not yet recruiting
Sponsor:
Information provided by:
Penn State University
ClinicalTrials.gov Identifier:
NCT00766558
First received: October 3, 2008
Last updated: NA
Last verified: September 2008
History: No changes posted
  Purpose

A technique that has been found to be effective at relieving the physical and psychological symptoms associated with inhibiting emotions and emotional thoughts is written emotional disclosure. The goal of this study is to evaluate the effectiveness of written emotional disclosure on the remediation of eating disorder behaviour, cognitions, and management of emotions.


Condition
Anorexia Nervosa
Bulimia Nervosa
Eating Disorder

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Study of the Efficacy of Written Emotional Disclosure on Eating Disorder Pathology

Resource links provided by NLM:


Further study details as provided by Penn State University:

Primary Outcome Measures:
  • Testing and behavioral changes [ Time Frame: 6-weeks ] [ Designated as safety issue: No ]

Estimated Enrollment: 50
Study Start Date: November 2008
Estimated Study Completion Date: December 2010
Estimated Primary Completion Date: December 2009 (Final data collection date for primary outcome measure)
Groups/Cohorts
1
2
Written disclosure
Participant is assigned a potential stress-producing topic for written disclosure.
Control group
Participant assigned a non-stressful writing condition.

  Eligibility

Ages Eligible for Study:   14 Years to 50 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Patients in the Penn State Hershey Adolescentand Adult Eating Disorders Partial Hospitalization Program

Criteria

Inclusion Criteria:

  • Willing to sign consent form

Exclusion Criteria:

  • Unwilling to sign consent form
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00766558

Contacts
Contact: Richard L Levine, MD 7175318006 rlevine@psu.edu
Contact: Martha P Levine, MD 7175317232 mlevine1@hmc.psu.edu

Locations
United States, Pennsylvania
Penn State College of Medicine Not yet recruiting
Hershey, Pennsylvania, United States, 17033
Principal Investigator: Richard L Levine, MD         
Sponsors and Collaborators
Penn State University
  More Information

No publications provided

Responsible Party: Penn State College of Medicine IRBs A, B, C and D, Kevin Gleeson, MD
ClinicalTrials.gov Identifier: NCT00766558     History of Changes
Other Study ID Numbers: 28860
Study First Received: October 3, 2008
Last Updated: October 3, 2008
Health Authority: United States: Institutional Review Board

Keywords provided by Penn State University:
anorexia
bulimia
eating disorder not otherwise specified

Additional relevant MeSH terms:
Anorexia
Anorexia Nervosa
Bulimia
Eating Disorders
Bulimia Nervosa
Signs and Symptoms, Digestive
Signs and Symptoms
Mental Disorders
Hyperphagia

ClinicalTrials.gov processed this record on July 26, 2014